Skip to main content

Table 2 Association between cytokine expression and presence of active disease in patients with SLE

From: Cytokine profiling in active and quiescent SLE reveals distinct patient subpopulations

 

Unadjusted

Adjusted for age and gender

Fully adjusteda

OR (95% CI)

p value

OR (95% CI)

p value

OR (95% CI)

p value

IL-21b

1.06 (0.99, 1.13)

0.081

1.08 (0.99, 1.17)

0.077

1.06 (0.95, 1.18)

0.326

CXCL13b

1.07 (0.97, 1.18)

0.178

1.08 (0.97, 1.19)

0.177

1.05 (0.94, 1.18)

0.385

BLySb

1.38 (0.96, 1.98)

0.079

1.58 (1.03, 2.42)

0.037

1.20 (0.82, 1.77)

0.350

IL-10

1.07 (1.01, 1.13)

0.013

1.08 (1.02, 1.14)

0.009

1.04 (0.99, 1.10)

0.143

IFNαb

1.27 (0.98, 1.64)

0.069

1.30 (0.99, 1.71)

0.056

1.14 (0.88, 1.48)

0.330

IL-18b

1.20 (1.05, 1.37)

0.009

1.25 (1.06, 1.47)

0.007

1.18 (0.98, 1.43)

0.075

PTX3c

1.33 (1.13, 1.56)

0.001

1.29 (1.11, 1.50)

0.001

1.23 (1.04, 1.46)

0.013

CXCL10

1.00 (1.00, 1.02)

0.022

1.01 (1.00, 1.02)

0.003

1.02 (1.00, 1.03)

0.008

IL-17

1.07 (1.01, 1.13)

0.020

1.06 (1.00, 1.13)

0.062

1.03 (0.98, 1.09)

0.279

MCP-1b

1.16 (1.00, 1.36)

0.056

1.20 (0.99, 1.45)

0.070

1.13 (0.90, 1.41)

0.294

  1. Logistic regression models to show the odds of having active disease for every 1 pg/ml increase in the concentration of cytokine
  2. SLE systemic lupus erythematosus, OR odds ratio, 95% CI 95% confidence intervals, CXCL chemokine (C-X-C motif) ligand, BLyS B lymphocyte stimulator, IFNα interferon alpha, PTX pentraxin-related protein, MCP monocyte chemotactic protein
  3. aModel adjusted for age, gender, disease duration, ethnicity (Caucasian vs non-Caucasian) and current steroid use
  4. bPer 100 pg/ml increase
  5. cPer 1000 pg/ml increase
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us